Stryker Corp SYK
We take great care to ensure that the data presented and summarized in this overview for STRYKER CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SYK
View all-
Vanguard Group Inc Valley Forge, PA32.7MShares$12.6 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY26.8MShares$10.4 Billion0.21% of portfolio
-
Greenleaf Trust Kalamazoo, MI17.7MShares$6.85 Billion58.48% of portfolio
-
State Street Corp Boston, MA14.8MShares$5.71 Billion0.22% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.1MShares$4.29 Billion0.46% of portfolio
-
Jpmorgan Chase & CO New York, NY10.8MShares$4.17 Billion0.32% of portfolio
-
Wellington Management Group LLP Boston, MA8.38MShares$3.24 Billion0.57% of portfolio
-
Geode Capital Management, LLC Boston, MA7.07MShares$2.73 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.84MShares$2.64 Billion0.53% of portfolio
-
Morgan Stanley New York, NY5.56MShares$2.15 Billion0.14% of portfolio
Latest Institutional Activity in SYK
Top Purchases
Top Sells
About SYK
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Insider Transactions at SYK
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 27
2025
|
Yin C Becker VP, Chief Corp Affairs Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,931
-8.2%
|
$1,146,021
$391.74 P/Share
|
Feb 27
2025
|
Yin C Becker VP, Chief Corp Affairs Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,980
+12.23%
|
$478,080
$96.64 P/Share
|
Feb 25
2025
|
Ronda E Stryker Director |
SELL
Bona fide gift
|
Indirect |
141,026
-3.75%
|
-
|
Feb 24
2025
|
Ronda E Stryker Director |
SELL
Bona fide gift
|
Indirect |
51,282
-1.35%
|
-
|
Feb 21
2025
|
Ronda E Stryker Director |
SELL
Bona fide gift
|
Indirect |
192,308
-4.98%
|
-
|
Feb 19
2025
|
Ronda E Stryker Director |
SELL
Bona fide gift
|
Indirect |
156,411
-3.9%
|
-
|
Feb 18
2025
|
Allan C. Golston Director |
SELL
Open market or private sale
|
Direct |
2,458
-14.16%
|
$941,414
$383.07 P/Share
|
Feb 18
2025
|
Allan C. Golston Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,147
-6.2%
|
$441,595
$385.18 P/Share
|
Feb 18
2025
|
Allan C. Golston Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,605
+16.31%
|
$439,810
$122.51 P/Share
|
Feb 13
2025
|
Ronda E Stryker Director |
SELL
Bona fide gift
|
Indirect |
307,691
-8.53%
|
-
|
Feb 05
2025
|
William E Berry Jr VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
733
+11.27%
|
-
|
Feb 03
2025
|
Andrew K Silvernail Director |
SELL
Payment of exercise price or tax liability
|
Direct |
903
-6.14%
|
$353,073
$391.29 P/Share
|
Feb 03
2025
|
Andrew K Silvernail Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,795
+20.51%
|
$352,935
$93.06 P/Share
|
Jan 31
2025
|
Ronda E Stryker Director |
SELL
Open market or private sale
|
Indirect |
201,392
-0.89%
|
$79,147,056
$393.32 P/Share
|
Jan 30
2025
|
Ronda E Stryker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,795
+32.91%
|
$352,935
$93.06 P/Share
|
Jan 29
2025
|
Spencer S Stiles Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,448
-8.96%
|
$2,151,960
$395.15 P/Share
|
Jan 29
2025
|
Spencer S Stiles Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
10,210
+14.37%
|
$949,530
$93.06 P/Share
|
Jan 29
2025
|
James Andrew Pierce Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,537
-8.54%
|
$2,187,115
$395.15 P/Share
|
Jan 29
2025
|
James Andrew Pierce Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
9,455
+12.72%
|
$879,315
$93.06 P/Share
|
Dec 31
2024
|
Glenn S Boehnlein VP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
203
-3.81%
|
$73,486
$362.26 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 90.6K shares |
---|---|
Exercise of conversion of derivative security | 258K shares |
Bona fide gift | 198 shares |
Payment of exercise price or tax liability | 196K shares |
---|---|
Open market or private sale | 731K shares |
Bona fide gift | 864K shares |